Identification of an exonic splicing silencer in exon 6A of the human VEGF gene

BMC Molecular Biology

Volumn 10, Issue , 2009, Pages

  Wang, Rui ^a   Crystal, Ronald G ^a   Hackett, Neil R ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN; GREEN FLUORESCENT PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; EXON; FLOW CYTOMETRY; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE MAPPING; GENE SEQUENCE; GENE SILENCING; GENE TRANSFER; HUMAN; HUMAN CELL; INTRON; MUTAGENESIS; OPEN READING FRAME; POINT MUTATION; RNA SPLICING; GENETIC TRANSFECTION; GENETICS; HUMAN GENOME; METABOLISM; NUCLEOTIDE SEQUENCE; REPORTER GENE; REPRODUCIBILITY; SILENCER ELEMENT;

BASE SEQUENCE; EXONS; GENES, REPORTER; GENOME, HUMAN; GREEN FLUORESCENT PROTEINS; HUMANS; MUTAGENESIS; REPRODUCIBILITY OF RESULTS; RNA SPLICING; SEQUENCE DELETION; SILENCER ELEMENTS, TRANSCRIPTIONAL; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 71049174588     PISSN: None     EISSN: 14712199     Source Type: Journal    
DOI: 10.1186/1471-2199-10-103     Document Type: Article

References (57)

1. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 2005, 9:777-794. 10.1111/j.1582-4934.2005.tb00379.x, 16364190.
2. Ferrara N, Houck KA, Jakeman LB, Winer J, Leung DW. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991, 47:211-218. 10.1002/jcb.240470305, 1791185.
3. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004, 25:581-611. 10.1210/er.2003-0027, 15294883.
4. White FC, Carroll SM, Kamps MP. VEGF mRNA is reversibly stabilized by hypoxia and persistently stabilized in VEGF-overexpressing human tumor cell lines. Growth Factors 1995, 12:289-301. 10.3109/08977199509028967, 8930020.
5. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995, 270:13333-13340. 10.1074/jbc.270.22.13333, 7768934.
6. Eyssen-Hernandez R, Ladoux A, Frelin C. Differential regulation of cardiac heme oxygenase-1 and vascular endothelial growth factor mRNA expressions by hemin, heavy metals, heat shock and anoxia. FEBS Lett 1996, 382:229-233. 10.1016/0014-5793(96)00127-5, 8605975.
7. Stavri GT, Zachary IC, Baskerville PA, Martin JF, Erusalimsky JD. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia. Circulation 1995, 92:11-14.
8. Stein I, Itin A, Einat P, Skaliter R, Grossman Z, Keshet E. Translation of vascular endo-thelial growth factor mRNA by internal ribosome entry: implications for translation under hypoxia. Mol Cell Biol 1998, 18:3112-3119. 108893, 9584152.
9. Akiri G, Nahari D, Finkelstein Y, Le SY, Elroy-Stein O, Levi BZ. Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Oncogene 1998, 17:227-236. 10.1038/sj.onc.1202019, 9674707.
10. Chung J, Bachelder RE, Lipscomb EA, Shaw LM, Mercurio AM. Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells. J Cell Biol 2002, 158:165-174. 10.1083/jcb.200112015, 2173018, 12105188.
11. Ladomery MR, Harper SJ, Bates DO. Alternative splicing inangiogenesis: the vascular endothelial growth factor paradigm. Cancer Lett 2007, 249:133-142. 10.1016/j.canlet.2006.08.015, 17027147.
12. Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, Ladomery MR, Harper SJ, Bates DO. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci 2008, 121:3487-3495. 10.1242/jcs.016410, 2613349, 18843117.
13. Woolard J, Nowak D, Ladomery M, Harper SJ, Bates DO. Splice factor regulation of alternative splicing of VEGFisoform families [abstract]. FASEB Journal 2006, 20:A539.
14. Lei J, Jiang A, Pei D. Identification and characterization of a new splicing variant of vascular endothelial growth factor: VEGF183. Biochim Biophys Acta 1998, 1443:400-406.
15. Jingjing L, Xue Y, Agarwal N, Roque RS. Human Muller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1999, 40:752-759.
16. Grutzkau A, Kruger-Krasagakes S, Baumeister H, Schwarz C, Kogel H, Welker P, Lippert U, Henz BM, Moller A. Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. Mol Biol Cell 1998, 9:875-884. 25314, 9529385.
17. Ng YS, Rohan R, Sunday ME, Demello DE, D'Amore PA. Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn 2001, 220:112-121. 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1093>3.0.CO;2-D, 11169844.
18. Bacic M, Edwards NA, Merrill MJ. Differential expressionof vascular endothelial growth factor (vascular permeability factor) forms in rat tissues. Growth Factors 1995, 12:11-15. 10.3109/08977199509003209, 8527159.
19. Cheung N, Wong MP, Yuen ST, Leung SY, Chung LP. Tissue-specific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon. Hum Pathol 1998, 29:910-914. 10.1016/S0046-8177(98)90195-2, 9744306.
20. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993, 4:1317-1326. 275767, 8167412.
21. Venables JP. Aberrant and alternative splicing in cancer. Cancer Res 2004, 64:7647-7654. 10.1158/0008-5472.CAN-04-1910, 15520162.
22. Carmeliet P, Ng YS, Nuyens D, Theilmeier G, Brusselmans K, Cornelissen I, Ehler E, Kakkar VV, Stalmans I, Mattot V. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 1999, 5:495-502. 10.1038/8379, 10229225.
23. Soker S, Miao HQ, Nomi M, Takashima S, Klagsbrun M. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J Cell Biochem 2002, 85:357-368. 10.1002/jcb.10140, 11948691.
24. Tokunaga T, Kijima H, Oshika Y, Fukushima Y, Abe Y, Ohnishi Y, Yamazaki H, Tsuchida T, Makuuchi H, Tamaoki N. Aberrant isoform of vascular endothelial growth factor 189 expression is correlated with xenotransplantability of human esophageal cancer. Oncol Rep 1998, 5:1115-1118.
25. Grunstein J, Masbad JJ, Hickey R, Giordano F, Johnson RS. Isoforms of vascular endo-thelial growth factor act in a coordinate fashion To recruit and expand tumor vasculature. Mol Cell Biol 2000, 20:7282-7291. 10.1128/MCB.20.19.7282-7291.2000, 86282, 10982845.
26. Tokunaga T, Nakamura M, Oshika Y, Ohnishi Y, Ueyama Y. Is xenotransplantability of human colon cancers in SCID mice affected byangiogenic factors?. J Natl Cancer Inst 1998, 90:400-401. 10.1093/jnci/90.5.400, 9498493.
27. Okamoto K, Oshika Y, Fukushima Y, Ohnishi Y, Tokunaga T, Tomii Y, Kijima H, Yamazaki H, Ueyama Y, Tamaoki N. Xenografts of human solid tumors frequently express cellular-associated isoform of vascular endothelial growth factor (VEGF) 189. Oncol Rep 1999, 6:1201-1204.
28. Whitlock PR, Hackett NR, Leopold PL, Rosengart TK, Crystal RG. Adenovirus-mediated transfer of a minigene expressing multiple isoforms of VEGF is more effective at inducing angiogenesis than comparable vectors expressing individual VEGF cDNAs. Mol Ther 2004, 9:67-75. 10.1016/j.ymthe.2003.09.014, 14741779.
29. Cheng SY, Nagane M, Huang HS, Cavenee WK. Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proc Natl Acad Sci USA 1997, 94:12081-12087. 10.1073/pnas.94.22.12081, 23709, 9342366.
30. Amano H, Hackett NR, Kaner RJ, Whitlock P, Rosengart TK, Crystal RG. Alteration of splicing signals in a genomic/cDNA hybrid VEGF gene to modify the ratio of expressed VEGF isoforms enhances safety of angiogenic gene therapy. Mol Ther 2005, 12:716-724. 10.1016/j.ymthe.2005.03.031, 16039163.
31. Stimpfl M, Tong D, Fasching B, Schuster E, Obermair A, Leodolter S, Zeillinger R. Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer. Clin Cancer Res 2002, 8:2253-2259.
32. Wang Z, Rolish ME, Yeo G, Tung V, Mawson M, Burge CB. Systematic identification and analysis of exonic splicing silencers. Cell 2004, 119:831-845. 10.1016/j.cell.2004.11.010, 15607979.
33. Stamm S, Riethoven JJ, Le TV, Gopalakrishnan C, Kumanduri V, Tang Y, Barbosa-Morais NL, Thanaraj TA. ASD: a bioinformatics resource on alternative splicing. Nucleic Acids Res 2006, 34:D46-D55. 10.1093/nar/gkj031, 1347394, 16381912.
34. Dreyfuss G, Matunis MJ, Pinol-Roma S, Burd CG. hnRNP proteins and the biogenesis of mRNA. Annu Rev Biochem 1993, 62:289-321. 10.1146/annurev.bi.62.070193.001445, 8352591.
35. Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO, Cui TG, Sugiono M, Waine E, Perrin R. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 2004, 64:7822-7835. 10.1158/0008-5472.CAN-04-0934, 15520188.
36. Cohen CD, Doran PP, Blattner SM, Merkle M, Wang GQ, Schmid H, Mathieson PW, Saleem MA, Henger A, Rastaldi MP. Sam68-like mammalian protein 2, identified by digital differential display as expressed by podocytes, is induced in proteinuria and involved in splice site selection of vascular endothelial growth factor. J Am Soc Nephrol 2005, 16:1958-1965. 10.1681/ASN.2005020204, 15901763.
37. Kevil CG, De BA, Payne DK, Coe LL, Laroux FS, Alexander JS. Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis. Int J Cancer 1996, 65:785-790. 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3, 8631593.
38. Bonano VI, Oltean S, Garcia-Blanco MA. A protocol forimaging alternative splicing regulation in vivo using fluorescence reporters in transgenic mice. Nat Protoc 2007, 2:2166-2181. 10.1038/nprot.2007.292, 17853873.
39. Singh G, Cooper TA. Minigene reporter for identificationand analysis of cis elements and trans factors affecting pre-mRNA splicing. Biotechniques 2006, 41:177-181. 10.2144/000112208, 16925019.
40. Spellman R, Rideau A, Matlin A, Gooding C, Robinson F, McGlincy N, Grellscheid SN, Southby J, Wollerton M, Smith CW. Regulation of alternative splicing by PTB and associated factors. Biochem Soc Trans 2005, 33:457-460. 10.1042/BST0330457, 15916540.
41. Newman EA, Muh SJ, Hovhannisyan RH, Warzecha CC, Jones RB, McKeehan WL, Carstens RP. Identification of RNA-binding proteins that regulate FGFR2 splicing through the use of sensitive and specific dual color fluorescence minigene assays. RNA 2006, 12:1129-1141. 10.1261/rna.34906, 1464843, 16603716.
42. Sheives P, Lynch KW. Identification of cells deficient insignaling-induced alternative splicing by use of somatic cell genetics. RNA 2002, 8:1473-1481. 1370353, 12515380.
43. Ellis PD, Smith CW, Kemp P. Regulated tissue-specific alternative splicing of enhanced green fluorescent protein transgenes conferred by alpha-tropomyosin regulatory elements in transgenic mice. J Biol Chem 2004, 279:36660-36669. 10.1074/jbc.M405380200, 15194683.
44. Nasim MT, Chowdhury HM, Eperon IC. A double reporterassay for detecting changes in the ratio of spliced and unspliced mRNA in mammalian cells. Nucleic Acids Res 2002, 30:e109. 10.1093/nar/gnf108, 137153, 12384611.
45. Pozzoli U, Sironi M. Silencers regulate both constitutiveand alternative splicing events in mammals. Cell Mol Life Sci 2005, 62:1579-1604. 10.1007/s00018-005-5030-6, 15905961.
46. Caputi M, Zahler AM. SR proteins and hnRNP H regulate thesplicing of the HIV-1 tev-specific exon 6D. EMBO J 2002, 21:845-855. 10.1093/emboj/21.4.845, 125874, 11847131.
47. Chen CD, Kobayashi R, Helfman DM. Binding of hnRNP H to an exonic splicing silencer is involved in the regulation of alternative splicing of the rat beta-tropomyosin gene. Genes Dev 1999, 13:593-606. 10.1101/gad.13.5.593, 316507, 10072387.
48. Crawford JB, Patton JG. Activation of alpha-tropomyosinexon 2 is regulated by the SR protein 9G8 and heterogeneous nuclear ribonucleoproteins H and F. Mol Cell Biol 2006, 26:8791-8802. 10.1128/MCB.01677-06, 1636816, 17000773.
49. Howell M, Borchers C, Milgram SL. Heterogeneous nuclear ribonuclear protein U associates with YAP and regulates its co-activation of Bax transcription. J Biol Chem 2004, 279:26300-26306. 10.1074/jbc.M401070200, 15096513.
50. Fogel BL, McNally MT. A cellular protein, hnRNP H, binds to the negative regulator of splicing element from Rous sarcoma virus. J Biol Chem 2000, 275:32371-32378. 10.1074/jbc.M005000200, 10934202.
51. Garneau D, Revil T, Fisette JF, Chabot B. Heterogeneous nuclear ribonucleoprotein F/H proteins modulate the alternative splicing of the apoptotic mediator Bcl-x. J Biol Chem 2005, 280:22641-22650. 10.1074/jbc.M501070200, 15837790.
52. Mauger DM, Lin C, Garcia-Blanco MA. HnRNP H and hnRNP F complex with Fox proteins to silence FGFR2 exon IIIc. Mol Cell Biol 2008, 28:5403-5419. 10.1128/MCB.00739-08, 2519734, 18573884.
53. Himmelspach M, Cavaloc Y, Chebli K, Stevenin J, Gattoni R. Titration of serine/arginine (SR) splicing factors during adenoviral infection modulates E1A pre-mRNA alternative splicing. RNA 1995, 1:794-806. 1369320, 7493325.
54. Akusjarvi G, Stevenin J. Remodelling of the host cell RNAsplicing machinery during an adenovirus infection. Curr Top Microbiol Immunol 2003, 272:253-286.
55. Magin-Lachmann C, Kotzamanis G, D'Aiuto L, Cooke H, Huxley C, Wagner E. In vitro and in vivo delivery of intact BAC DNA -- comparison of different methods. J Gene Med 2004, 6:195-209. 10.1002/jgm.481, 14978773.
56. Hibbitt OC, Harbottle RP, Waddington SN, Bursill CA, Coutelle C, Channon KM, Wade-Martins R. Delivery and long-term expression of a 135 kb LDLR genomic DNA locus in vivo by hydrodynamic tail vein injection. J Gene Med 2007, 9:488-497. 10.1002/jgm.1041, 17471590.
57. Muraki M, Ohkawara B, Hosoya T, Onogi H, Koizumi J, Koizumi T, Sumi K, Yomoda J, Murray MV, Kimura H. Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem 2004, 279:24246-24254. 10.1074/jbc.M314298200, 15010457.